Association between OGG1 Ser326Cys and APEX1 Asp148Glu polymorphisms and breast cancer risk: a meta-analysis by Qiliu Peng et al.
Peng et al. Diagnostic Pathology 2014, 9:108
http://www.diagnosticpathology.org/content/9/1/108RESEARCH Open AccessAssociation between OGG1 Ser326Cys and APEX1
Asp148Glu polymorphisms and breast cancer risk:
a meta-analysis
Qiliu Peng1, Yu Lu1, Xianjun Lao1, Zhiping Chen2, Ruolin Li3, Jingzhe Sui1, Xue Qin1* and Shan Li1Abstract
Background: The base excision repair (BER) pathway removes DNA damage caused by ionizing radiation, reactive
oxidative species and methylating agents. OGG1 and APE1 are two important genes in the BER pathway. Many
epidemiological studies have evaluated the association between polymorphisms in the two BER genes (OGG1
Ser326Cys and APE1 Asp148Glu) and breast cancer risk. However, the results are inconsistent.
Methods: We searched the electronic databases including PubMed, Embase and Cochrane library for all eligible
studies for the period up to February 2014. Data were extracted by two independent authors and pooled odds
ratios (ORs) with corresponding 95% confidence intervals (CIs) were used to assess the strength of the association.
Results: A total of 17 studies including 9,040 cases and 10,042 controls were available for OGG1 Ser326Cys
polymorphism and 7 studies containing 2,979 cases and 3,111 controls were included for APE1 Asp148Glu
polymorphism. With respect to OGG1 Ser326Cys polymorphism, we did not find a significant association with
breast cancer risk when all eligible studies were pooled into the meta-analysis. However, in subgroup analyses by
ethnicity and menopausal status, statistical significant increased breast cancer risk was found in Asian populations
(Cys/Cys vs. Ser/Ser: OR = 1.157, 95% CI 1.013–1.321, P = 0.011; Cys/Cys vs. Ser/Cys + Ser/Ser: OR = 1.113, 95% CI
1.009–1.227, P = 0.014) and postmenopausal patients (Cys/Cys vs. Ser/Cys + Ser/Ser: OR = 1.162, 95% CI 1.003–1.346,
P = 0.024). In subgroup analysis according to quality score, source of control, and HWE in controls, no any significant
association was detected. With respect to APE1 Asp148Glu polymorphism, no significant association with breast cancer
risk was demonstrated in the overall and stratified analyses.
Conclusions: The present meta-analysis suggests that the OGG1 Ser326Cys polymorphism may be a risk factor for
breast cancer in Asians and postmenopausal patients. Further large and well-designed studies are needed to
confirm this association.
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Breast cancer is currently the most frequently occurring
cancer and one of the leading causes of cancer-related
death of females worldwide, which has become a major
public health challenge [1,2]. Breast cancer is a heteroge-
neous disease such that they may have different prognoses
and respond to therapy differently despite similarities in
histological types, grade and stage [3,4]. Because of the
heterogeneity of breast cancer, the mechanism of breast
carcinogenesis is still not fully understood. It has been well
established that exposure to various endogenous and ex-
ogenous mutagens or carcinogens played a critical role in
the development of breast cancer [5,6]. The exposures can
lead to DNA damage which, if remained unrepaired, may
result in genetic instability and unregulated cell growth,
and eventually breast cancer [7]. The DNA repairing sys-
tems, composed of many DNA repair genes, play a critical
role in removing damaged genes resulting from endogen-
ous and exogenous mutagenic exposures, and maintaining
the genomic integrity and preventing carcinogenesis.
The base excision repair (BER) pathway is one of the
most important DNA repair mechanisms responsible
for the repair of DNA damage. It is the most common
route for removal of small lesions from DNA and is an
important part of cellular defense against a large variety
of structurally unrelated DNA lesions. It is believed to
be the predominant pathway used for removal of oxi-
dized and many alkylated bases [8,9]. BER is initiated by
recognition and excision of damaged base by the specific
DNA glycosylase. Mammalian cells contain a series of dif-
ferent genes (each with a specialized function), of which
8-oxoguanine glycosylase-1 (OGG1), and apurinic/apyimi-
dinic endonuclease 1 (APE1) genes are two key enzymes
in this repair pathway [10]. OGG1 maps on chromosome
3p26.2 and encodes the DNA repair enzyme OGGl re-
sponsible for the excision of 8-oxo-7, 8-dihydroguanine
(8-oxoG) and other oxidatively damaged DNA bases.
The APEX1 gene consists of five exons and four introns
spanning 2.21 kb. This gene is located on chromosome
14q11.2–q12. By hydrolyzing 3'-blocking fragments from
oxidized DNA, APEX1 produces normal 3'-hydroxyl nu-
cleotide termini that are necessary for DNA repair synthe-
sis and ligation at single- or double-strand breaks [11,12].
Many single nucleotide polymorphisms in the OGG1 and
APEX1 gene have been reported, including the commonly
occurring Ser326Cys in OGG1 (rs1052133 in dbSNP) and
Asp148Glu in APEX1 (rs3136820 in dbSNP). These non-
conservative amino acid alterations have been reported to
reduce DNA repair activity and consequently increase
cancer risk [13,14].
To date, many epidemiological studies have been
performed to evaluate the association between OGG1
Ser326Cys and APEX1 Asp148Glu polymorphisms and
breast cancer risk, but the results remain conflictingrather than conclusive. With respect to APEX1 Asp148Glu
polymorphism, a meta-analysis by Wu et al. [15] found
that the APEX1 Asp148Glu polymorphism may not con-
tribute to breast cancer risk, however, they failed to include
all eligible studies in the meta-analysis [16,17], which make
their conclusions questionable. With respect to OGG1
Ser326Cys polymorphism, two meta-analyses [18,19] in-
vestigating the same hypothesis, quite similar in methods
and performed almost at the same time, yielded different
conclusions. Furthermore, the two previous meta-analyses
did not cover all eligible studies [16,17,20-22]. The exact
relationship between genetic polymorphisms of OGG1
Ser326Cys and APEX1 Asp148Glu and breast cancer
susceptibility has not been entirely established. To pro-
vide the most comprehensive assessment of the associa-
tions between OGG1 Ser326Cys and APEX1 Asp148Glu
polymorphisms and breast cancer risk, we performed an
updated meta-analysis of all available studies.Methods
Search strategy
We conducted a comprehensive literature search in
PubMed, Embase, and Cochrane library databases for
all eligible studies (updated to February 01, 2014) using
the following search strategy: (“breast cancer”) and
(“OGG1”, “hOGG1”, “APEX1” or “APEX”) and (“poly-
morphism”, “variation”, “mutation”, “genotype”, or “genetic
polymorphism”). There was no restriction on time period,
sample size, population, language, or type of report. All eli-
gible studies were retrieved and their references were
checked for other relevant studies. The literature retrieval
was performed in duplication by two independent re-
viewers (Qiliu Peng and Shi Yang). When multiple pub-
lications reported on the same or overlapping data, we
chose the most recent or largest population. When a
study reported the results on different subpopulations,
we treated it as separate studies in the meta-analysis.Selection criteria
Studies were included if they met the following criteria:
(1) Case–control studies which evaluated the association
between OGG1 Ser326Cys and APEX1 Asp148Glu poly-
morphisms and breast cancer risk; (2) had an odds ratio
(OR) with 95% confidence interval (CI) or other avail-
able data for estimating OR (95% CI); and (3) control
population did not contain malignant tumor patients.
Studies were excluded if one of the following existed: (1)
no control population; (2) duplicate of previous publica-
tion; and (3) insufficient information for data extraction;
(4) Family-based studies of pedigrees with several affected
cases per family were also excluded, because their analysis
is based on linkage considerations.
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Two investigators (Qiliu Peng and Yu Lu) independently
reviewed and extracted data from all eligible studies. To
ensure the accuracy of the information extracted, the
two investigators checked the data extraction results and
reached consensus on all of the items. If different results
were generated, they would check the data again and
have a discussion to come to an agreement. If these two
authors could not reach a consensus, another author
(Xue Qin) was consulted to resolve the dispute and a
final decision was made by the majority of the votes.
Data extracted from eligible studies included the first au-
thor, year of publication, country of origin, ethnicity,
genotyping method, matching criteria, source of control,
breast cancer confirmation, total numbers of cases and
controls and genotype frequencies of cases and controls.
When data were otherwise unavailable, we contacted the
corresponding author by e-mail for original information.
Ethnic backgrounds were categorized as Caucasian, Asian,
and Africans. When a study did not state the ethnic des-
cendent or if it was impossible to separate participants
according to such phenotype, the group reported was
termed as “mixed ethnicity”. Menopausal status was di-
vided into premenopausal and postmenopausal and was
additionally recorded for the stratified analysis.
Quality score evaluation
The quality of eligible studies was evaluated independently
by two authors (Xue Qin and Qiliu Peng) according to a
set of predefined criteria (Additional file 1: Table S1) based
on the scale of Thakkinstian et al. [23]. The revised criteria
cover the representativeness of cases, source of controls,
ascertainment of breast cancer, total sample size, quality
control of genotyping methods, and Hardy-Weinberg
equilibrium (HWE) in the control population. Disagree-
ments were resolved by consensus. Scores ranged from 0
(lowest) to 10 (highest). Articles with scores equal to or
less than 6 were considered “low-quality” studies, whereas
those with scores higher than 6 were considered “high-
quality” studies.
Statistical analysis
The strength of the association between OGG1 Ser326Cys
and APEX1 Asp148Glu polymorphisms and breast cancer
risk was assessed by odds ratios (ORs) with 95% confi-
dence intervals (CIs). The significance of the pooled OR
was determined by Z test and a p value less than 0.05
was considered significant. The association of OGG1
Ser326Cys and APEX1 Asp148Glu polymorphisms with
breast cancer risk was assessed using additive models,
recessive model, and dominant model. Heterogeneity
assumption was checked by a chi-square-based Q-test
[24]. A Ph value equal to or greater than 0.10 for the Q-
test indicates a lack of heterogeneity among studies, andso the fixed-effects model was used for the meta-analysis
[25]. Otherwise, the random-effects model was used [26].
Subgroup analyses were performed by ethnicity, meno-
pausal status, quality score, source of control, and HWE
in controls. Sensitivity analysis was performed by sequen-
tial omission of individual studies. For each polymorph-
ism, publication bias was evaluated using a funnel plot
and Egger’s regression asymmetry test. The distribution of
the genotypes in the control population was tested for
HWE using a goodness-of-fit Chi-square test. All analyses
were performed using Stata software, version 12.0 (Stata
Corp., College Station, TX). All p values were two-sided.
To ensure the reliability and the accuracy of the results,
two authors entered the data into the statistical software
programs independently with the same results.
Results
Study characteristics
Based on our search criteria, 24 studies relevant to the
role of OGG1 Ser326Cys and APEX1 Asp148Glu poly-
morphisms on breast cancer susceptibility were identified.
Seven of these articles were excluded: one was a review
[27], one contained overlapping data [28], two did not
present sufficient data for calculating OR and 95% CI
[29,30], and three were meta-analysis [15,18,19]. Manual
search of references cited in the eligible studies identified
1 additional article [16]. As a result, a total of 18 relevant
studies [16,17,20-22,31-43] met the inclusion criteria for
the meta-analysis. Among them, two studies [32,42] con-
tained data on two different ethnic groups, and we treated
them independently. Therefore, a total of 20 separate
comparisons were finally included in the meta-analysis
(Figure 1). Of all eligible studies, 13 studies evaluated
the OGG1 Ser326Cys polymorphism, 3 studies evalu-
ated the APEX1 Asp148Glu polymorphism, and 4 stud-
ies evaluated OGG1 Ser326Cys and APEX1 Asp148Glu
polymorphisms simultaneously. Therefore, a total of 17
studies including 9,040 cases and 10,042 controls were
available for hOGG1 Ser326Cys polymorphism and 7
studies containing 2,979 cases and 3,111 controls were
included for APE1 Asp148Glu polymorphism. Table 1
list all essential information such as the publication year,
first author, country, ethnicity, sample size, genotyping
methods, source of controls, matching criteria, and breast
cancer confirmation for OGG1 Ser326Cys and APEX1
Asp148Glu polymorphisms. The genotype distributions
of the controls in 2 studies [32,41] were not consistent
with HWE for OGG1 Ser326Cys polymorphism and 1
was not consistent with HWE for APEX1 Asp148Glu
polymorphism [17].
Meta-analysis results
Table 2 lists the main results of meta-analysis of OGG1
Ser326Cys polymorphism and breast cancer risk. The
Figure 1 Flowchart of selection of studies for inclusion in meta-analysis.
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overall populations and all subgroup analyses (all Ph
values were larger than 0.1), thus the fixed-effects model
was used to pool the results. Overall, significant elevated
breast cancer risk was not found when all studies were
pooled into the meta-analysis. When stratified by quality
score, source of control, and HWE in controls, signifi-
cant increased breast cancer risk was also not detected
in all subgroups. However, in subgroup analysis by eth-
nicity, significant increased breast cancer risk was found
in Asians (Cys/Cys vs. Ser/Ser: OR = 1.157, 95% CI 1.013–
1.321, P = 0.011; Cys/Cys vs. Ser/Cys + Ser/Ser: OR =
1.113, 95% CI 1.009–1.227, P = 0.014; Figure 2) but not in
Caucasians. In stratified analysis by menopausal status,
significant increased breast cancer risk was observed in
postmenopausal patients (Cys/Cys vs. Ser/Cys + Ser/Ser:
OR = 1.162, 95% CI 1.003–1.346, P = 0.024; Figure 3) but
not in premenopausal subjects.
Table 3 lists the main results of meta-analysis of APEX1
Asp148Glu polymorphism and breast cancer risk. When
all 7 studies were pooled into the meta-analysis, there was
no evidence of significant association between APEX1
Asp148Glu polymorphism and breast cancer risk (Glu/Glu
vs. Asp/Asp: OR = 0.948, 95% CI = 0.817–1.101, P = 0.486;
Asp/Glu vs. Asp/Asp: OR = 0.975, 95% CI = 0.790–1.204,
P = 0.814; Glu/Glu + Asp/Glu vs. Asp/Asp: OR = 0.959,
95% CI = 0.803–1.146, P = 0.646; Glu/Glu vs. Asp/Glu +
Asp/Asp: OR = 0.961, 95% CI = 0.846–1.091, P = 0.540). Instratified analyses by ethnicity, menopausal status, quality
score, source of control, and HWE in controls, statistically
significant association was also not found in all subgroups.
Sensitivity analysis
Sensitivity analysis was performed by sequential omission
of individual studies for both OGG1 Ser326Cys and
APEX1 Asp148Glu polymorphisms. For analyses of pool-
ing more than three individual studies, the significance of
ORs was not influenced excessively by omitting any single
study (data not shown). For the OGG1 Ser326Cys poly-
morphism, sensitivity analysis was further performed by
omitting the studies by Choi et al. [32] and Ming-Shiean
et al. [41] in which the control populations were not in ac-
cordance with HWE. The significance of all ORs was not
altered after excluding these two studies. For the APEX1
Asp148Glu polymorphism, a sensitivity analysis was also
further performed by omitting the study by Kim et al. [17]
in which the control populations were deviated from
HWE, and the significance of all ORs was also not altered.
Publication bias
Begg’s funnel plot and Egger’s test were performed to ac-
cess the publication bias in this meta-analysis. The shape
of the funnel plot did not reveal any evidence of obvious
asymmetry. Then, the Egger’s test was used to provide
statistical evidence of funnel plot symmetry. The results
still did not suggest any evidence of publication bias in











SNP studied HWE(P value)
Ser326Cys Asp148Glu
Vogel [31] Caucasian 425/434 Sequencing Age, menopausal
status
PB NA 7 OGG1 Ser326Cys 0.175 —
Choi [32] Asian 265/284 PCR-RFLP NA HB Histopatho- 6.5 OGG1 Ser326Cys 0.048 —
Choi [32] Asian 201/184 PCR-CTPP Age HB Histo- 6 OGG1 Ser326Cys 0.914 —
Huang [16] Asian 136/232 PCR-RFLP Age HB Patho- 6 OGG1 Ser326Cys
APEX1 Asp148Glu
0.525 0.565
Zhang [33] Caucasian 1571/1244 TaqMan Age PB NA 8 OGG1 Ser326Cys
APEX1 Asp148Glu
0.930 0.456
Rossner [34] Caucasian 1041/1093 FP-TDI Age PB NA 8 OGG1 Ser326Cys 0.857 —
Cai [35] Asian 1102/1167 TaqMan Age PB NA 8 OGG1 Ser326Cys 0.080 —
Synowiec [36] Caucasian 41/48 PCR-RFLP Age HB NA 2.5 OGG1 Ser326Cys 0.507 —
Sangrajrang [37] Asian 506/424 Capillary PCR Region, menopausal
status, drinking,
smoking





Caucasian 100/106 PCR-RFLP Age HB NA 2.5 OGG1 Ser326Cys 0.988 —
Loizidou [39] Caucasian 1108/1174 TaqMan Age PB Patho- 9.5 OGG1 Ser326Cys 0.499 —
Sterpone [28] Caucasian 43/34 PCR-SSCP Age, gender HB NA 3 OGG1 Ser326Cys 0.577 —
Ming-Shiean [41] Asian 401/533 TaqMan Age HB Patho- 6.5 OGG1 Ser326Cys 0.034 —
Roberts [20] Caucasian 1054/1887 MALDI-TOF Age, race PB Histo- 8 OGG1 Ser326Cys 0.543 —
Smolarz [22] Caucasian 70/70 PCR-RFLP Age HB Histo- 5 OGG1 Ser326Cys 0.473 —
Kim [17] Asian 346/351 ASPE Age, BMI, smoking,
drinking
HB Histo- 6.5 OGG1 Ser326Cys
APEX1 Asp148Glu
0.296 0.012
Xie [21] Asian 630/777 Sequencing Age, BMI,
menopausal status
HB Patho- 7 OGG1 Ser326Cys 0.161 —
Smith [42] Caucasian 319/405 TaqMan Age, race HB Histopatho- 7 APEX1 Asp148Glu — 0.507
Smith [42] African 53/75 TaqMan Age, race HB Histopatho- 6 APEX1 Asp148Glu — 0.566
Jelonek [43] Caucasian 91/412 PCR-RFLP Age, gender PB NA 5 APEX1 Asp148Glu — 0.092
BC, breast cancer; Histopatho-, Histopathologically confirmed; Histo-, Histologically confirmed; Patho-, Pathologically confirmed; NA, Not available; PB, Population–based; HB, Hospital–based; HWE, Hardy–Weinberg
equilibrium in control population; PCR–RFLP, Polymerase chain reaction-restriction fragment length polymorphism; PCR-CTPP, Polymerase chain reaction with confronting two-pair primers; FP-TDI, Template-directed
primer extension and detection by fluorescence polarization; PCR-SSCP, Polymerase chain reaction-single strand conformation polymorphism; MALDI-TOF, Matrix-assisted laser desorption/ionization-time of flight mass






















Cys/Cys + Ser/Cys vs. Ser/Ser
(Dominant model)
Cys/Cys vs. Ser/Cys + Ser/Ser
(Recessive model)
OR (95% CI) P/Ph OR (95% CI) P/Ph OR (95% CI) P/Ph OR (95% CI) P/Ph
Overall 17 1.073(0.968-1.190) 0.180/0.485 0.986(0.923-1.054) 0.679/0.594 1.001(0.940-1.067) 0.971/0.501 1.079(0.993-1.172) 0.074/0.580
Ethnicity
Caucasian 9 0.956(0.812-1.127) 0.595/0.635 0.964(0.891-1.043) 0.357/0.218 0.967(0.897-1.043) 0.388/0.271 0.995(0.850-1.164) 0.945/0.958
Asian 8 1.157(1.013-1.321) 0.011/0.492 1.043(0.922-1.178) 0.505/0.946 1.085(0.967-1.218) 0.166/0.903 1.113(1.009-1.227) 0.014/0.173
Menopausal status
Premenopausal 7 1.153(0.957-1.388) 0.134/0.215 1.030(0.897-1.182) 0.677/0.995 1.052(0.923-1.199) 0.449/0.855 1.175(0.929-1.487) 0.178/0.149
Postmenopausal 9 1.154(0.965-1.380) 0.116/0.710 0.962(0.863-1.072) 0.482/0.202 0.994(0.896-1.102) 0.903/0.351 1.162(1.003-1.346) 0.024/0.570
Quality score
>6 11 1.093(0.980-1.218) 0.110/0.845 0.993(0.928-1.063) 0.841/0.941 1.007(0.944-1.075) 0.829/0.912 1.086(0.995-1.186) 0.065/0.507
≤6 6 0.916(0.664-1.262) 0.590/0.110 0.879(0.667-1.159) 0.361/0.157 0.910(0.702-1.180) 0.478/0.170 1.017(0.789-1.310) 0.899/0.446
Source of control
HB 11 1.134(0.975-1.320) 0.104/0.164 0.966(0.842-1.107) 0.615/0.384 1.029(0.904-1.170) 0.669/0.238 1.166(0.945-1.307) 0.107/0.462
PB 6 1.023(0.889-1.178) 0.750/0.997 0.992(0.920-1.071) 0.845/0.656 0.993(0.923-1.067) 0.843/0.802 0.987(0.874-1.114) 0.829/0.987
HWE in controls
Yes 15 1.071(0.960-1.195) 0.218/0.343 0.989(0.924-1.059) 0.757/0.468 1.002(0.939-1.069) 0.961/0.362 1.068(0.976-1.168) 0.465/0.154
No 2 1.086(0.803-1.471) 0.592/0.993 0.929(0.693-1.244) 0.620/0.717 0.993(0.755-1.307) 0.961/0.765 1.142(0.923-1.413) 0.223/0.726















Figure 2 Forest plots of OGG1 Ser326Cys polymorphism and breast cancer risk in subgroup analysis by ethnicity using a fixed-effect
model (Recessive model Cys/Cys vs. Ser/Cys + Ser/Ser).
Figure 3 Forest plots of OGG1 Ser326Cys polymorphism and breast cancer risk in postmenopausal patients using a fixed-effect model
(Recessive model Cys/Cys vs. Ser/Cys + Ser/Ser).
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Table 3 Meta-analysis of APEX1 Asp148Glu polymorphism and breast cancer risk
Analysis No. of
studies
Glu/Glu vs. Asp/Asp (Homozygote) Asp/Glu vs. Asp/Asp (Heterozygote) Glu/Glu + Asp/Glu vs. Asp/Asp
(Dominant model)
Glu/Glu vs. Asp/Glu + Asp/Asp
(Recessive model)
OR (95% CI) P/Ph OR (95% CI) P/Ph OR (95% CI) P/Ph OR (95% CI) P/Ph
Overall 7 0.948(0.817-1.101) 0.486/0.508 0.975(0.790-1.204) 0.814/0.028 0.959(0.803-1.146) 0.646/0.074 0.961(0.846-1.091) 0.540/0.572
Ethnicity
Caucasian 3 1.019(0.850-1.221) 0.842/0.395 0.928(0.670-1.285) 0.651/0.071 0.955(0.717-1.271) 0.751/0.097 1.042(0.897-1.211) 0.590/0.839
Asian 3 0.813(0.620-1.066) 0.135/0.455 1.031(0.681-1.560) 0.886/0.017 0.968(0.680-1.378) 0.855/0.035 0.873(0.604-1.091) 0.142/0.847
African 1 0.948(0.817-1.101) 0.794/— 0.870(0.404-1.870) 0.720/— 0.870(0.426-1.774) 0.701/— 0.933(0.353-2.469) 0.889/—
Menopausal status
Premenopausal 2 0.895(0.662-1.209) 0.469/0.509 0.938(0.744-1.181) 0.584/0.688 0.921(0.741-1.145) 0.460/0.602 0.927(0.716-1.201) 0.567/0.556
Postmenopausal 2 0.882(0.515-1.510) 0.648/0.096 1.046(0.847-1.290) 0.678/0.644 1.021(0.839-1.243) 0.835/0.323 0.972(0.782-1.208) 0.797/0.113
Quality score
>6 4 0.946(0.806-1.109) 0.491/0.351 0.999(0.760-1.313) 0.994/0.008 0.973(0.779-1.215) 0.807/0.031 0.952(0.831-1.091) 0.479/0.266
≤6 3 0.968(0.637-1.472) 0.880/0.368 0.898(0.642-1.256) 0.528/0.389 0.907(0.661-1.245) 0.547/0.303 1.024(0.719-1.456) 0.897/0.716
Source of control
HB 5 0.821(0.659-1.025) 0.081/0.809 0.921(0.669-1.268) 0.612/0.011 0.898(0.697-1.157) 0.405/0.055 0.864(0.709-1.052) 0.146/0.642
PB 2 1.070(0.874-1.309) 0.513/0.398 1.049(0.882-1.248) 0.589/0.538 1.055(0.896-1.242) 0.521/0.450 1.037(0.878-1.226) 0.667/0.562
HWE in controls
Yes 6 0.941(0.803-1.104) 0.456/0.390 0.930(0.818-1.057) 0.268/0.264 0.929(0.824-1.048) 0.232/0.258 0.989(0.864-1.132) 0.869/0.650
No 1 1.001(0.654-1.531) 0.997/— 1.345(0.904-2.162) 0.211/— 1.362(0.994-1.868) 0.055/— 0.774(0.532-1.126) 0.180/—
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http://www.diagnosticpathology.org/content/9/1/108OGG1 Ser326Cys (P = 0.104 for Cys/Cys vs. Ser/Ser;
P = 0.187 for Ser/Cys vs. Ser/Ser; P = 0.560 for recessive
model Cys/Cys vs. Ser/Cys + Ser/Ser, Figure 4A; and
P = 0.339 for dominant model Cys/Cys + Ser/Cys vs. Ser/
Ser) and APEX1 Asp148Glu (P = 0.535 for Glu/Glu vs.
Asp/Asp; P = 0.789 for Asp/Glu vs. Asp/Asp; P = 0.504
for recessive model Glu/Glu vs. Asp/Glu + Asp/Asp,
Figure 4B; and P = 0.766 for dominant model Glu/Glu +
Asp/Glu vs. Asp/Asp) polymorphisms.
Discussion
Maintenance of genomic integrity by DNA repair genes
is an essential component of normal cell homeostasis
necessary to cell growth, differentiation, and apoptosis
[7,44]. Previous evidence indicated that reduced DNA
repair capacity, due to various DNA repair gene polymor-
phisms, is associated with increased risk and susceptibility
to cancers [45,46]. BER pathway is one of the most im-
portant DNA repair mechanisms responsible for the re-
pair of DNA damage. It was initiated by recognition and
excision of damaged base by the specific DNA glycosylase.
OGG1 and APEX1 are both central players in the BER
pathway. Many epidemiological studies have been per-
formed to evaluate the role of OGG1 Ser326Cys and
APEX1 Asp148Glu polymorphisms on breast cancer risk;
however, the results remained conflicting and contradict-
ory. The conflicting results are possibly because of the
small effect of OGG1 Ser326Cys and APEX1 Asp148Glu
polymorphisms on cancer risk or the relatively low sta-
tistical power of individual published studies. To provide
the most comprehensive assessment of the association
between OGG1 Ser326Cys and APEX1 Asp148Glu poly-
morphisms and breast cancer risk, we performed this
meta-analysis of all available studies. Our results suggestedFigure 4 Funnel plot analysis to detect publication bias. Each point re
for recessive model Cys/Cys vs. Ser/Cys + Ser/Ser of OGG1 Ser326Cys polym
model Glu/Glu vs. Asp/Glu + Asp/Asp of APEX1 Asp148Glu polymorphism ithat the OGG1 Ser326Cys polymorphism was significantly
associated with increased breast cancer risk in Asian pop-
ulations and postmenopausal patients. However, our data
did not support a significant association between APEX1
Asp148Glu polymorphism and breast cancer risk both in
the pooled analysis and stratified analyses.
This finding may be biologically plausible. Oxidative
DNA damage induced by reactive oxygen species (ROS)
is involved in the process of carcinogenesis. Reactive
oxygen species could be generated from estrogen metab-
olism through catechol estrogen redox cycling [47,48]. If
not quenched, these reactive oxygen species may cause
oxidative DNA damage and increase breast cancer risk.
It has been suggested that 8-hydroxyguanine, a major
product of oxidative DNA damage, plays an important
role in carcinogenesis given its abundant and highly
mutagenic properties [49]. 8-Hydroxyguanine is subjected
to BER, especially via the 8-oxoguanine DNA glycosylase
(OGG1) catalyzing the release of 8-hydroxy-2'-deoxygua-
nosine and the cleavage of DNA at the AP site. Variants in
the OGG1 gene might alter protein structure or function
or create alternatively spliced proteins which may influ-
ence BER efficiency and hence affect individual suscepti-
bility to cancers. It was reported that the OGG1 326Cys
variant enzyme have lower activity than the 326Cys en-
zyme [50]. More importantly, the homozygous variant
genotype OGG1 326Cys has been shown associated with
increased risk for many different types of cancers, includ-
ing colorectal cancer [51], hepatocellular carcinoma [52]
and lung cancer [53].
In the stratification analysis of ethnicity, we found an evi-
dence for the association between the hOGG1 Ser326Cys
polymorphism and breast cancer susceptibility among
Asians but not Caucasians. A possible reason for thepresents a separate study for the indicated association. A Funnel plot
orphism in the overall analysis (P = 0.560); B Funnel plot for recessive
n overall analysis (P = 0.504).
Peng et al. Diagnostic Pathology 2014, 9:108 Page 10 of 11
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and gene–environment interactions. We observed a wide
variation of the Cys allele frequencies of control resources
in Asian (0.52) and Caucasian (0.24) population that were
very close to that obtained from the HapMap Project
(0.50 for CHB and 0.22 for CEU), and this different allele
frequency might account for the discrepancies between
the hOGG1 Ser326Cys polymorphism and breast cancer
susceptibility among different ethnicity.
Previous evidence suggested that the menopausal status
was one of the important risk factors for the development
of breast cancer. So we carried out subgroup analysis ac-
cording to menopausal status in this meta-analysis. Our
results suggested a significant increased breast cancer risk
in postmenopausal patients (Cys/Cys vs. Ser/Cys + Ser/
Ser: OR = 1.162, 95% CI 1.003–1.346, P = 0.024) but not in
premenopausal subjects. Though results from available
studies investigating OGG1 Ser326Cys polymorphism and
breast cancer risk have been inconsistent, our results
are consistent with the results of the large sample study
by Sangrajrang et al. [37]. The most possible reason for
this discrepancy in premenopausal and postmenopausal
patients is that the OGG1 Ser326Cys polymorphism
plays different roles in repairing oxidative DNA damage
resulting from estrogen metabolism in patients with
different menopausal status.
Some limitations of this meta-analysis should be ad-
dressed. First, in subgroup analysis by ethnicity, the in-
cluded studies regarded only Asians and Caucasians for
OGG1 Ser326Cys polymorphism. Data concerning other
ethnicities such as Africans were not found. Thus, add-
itional studies are warranted to evaluate the effect of this
functional polymorphism on breast cancer risk in different
ethnicities, especially in Africans. Second, our results were
based on unadjusted estimates. We did not perform the
analysis adjusted for other covariates such as age, obesity,
drinking and smoking status, use of contraceptives, envi-
ronment factors, and so on, because of the unavailable
original data of the eligible studies.
Conclusions
The meta-analysis provided a more precise estimation
based on larger sample size compared with the individual
studies and previous meta-analysis. Our study suggested
that OGG1 Ser326Cys polymorphism might contribute
to breast cancer risk, especially in Asian populations
and postmenopausal patients. In order to further verify
our findings, large well designed epidemiological studies
are warranted.
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